Integrated Proteomics Characterization of NLRP3 Inflammasome Inhibitor MCC950 in Monocytic Cell Line Confirms Direct MCC950 Engagement with Endogenous NLRP3
Inhibition of the NLRP3 inflammasome is a promising strategy for the development of new treatments for inflammatory diseases. MCC950 is a potent and selective small-molecule inhibitor of the NLRP3 pathway and has been validated in numerous species and disease models. Although the capacity of MCC950 to block NLRP3 signaling is well-established, it is still critical to identify the mechanism of action and molecular targets of MCC950 to inform and derisk drug development. Quantitative proteomics performed in disease-relevant systems provides a powerful method to study both direct and indirect pharmacological responses to small molecules to elucidate the mechanism of action and confirm target engagement. A comprehensive target deconvolution campaign requires the use of complementary chemical biology techniques. Here we applied two orthogonal chemical biology techniques: compressed Cellular Thermal Shift Assay (CETSA) and photoaffinity labeling chemoproteomics, performed under biologically relevant conditions with LPS-primed THP-1 cells, thereby deconvoluting, for the first time, the molecular targets of MCC950 using chemical biology techniques. In-cell chemoproteomics with inlysate CETSA confirmed the suspected mechanism as the disruption of inflammasome formation via NLRP3. Further cCETSA (c indicates compressed) in live cells mapped the stabilization of NLRP3 inflammasome pathway proteins, highlighting modulation of the targeted pathway. This is the first evidence of direct MCC950 engagement with endogenous NLRP3 in a human macrophage cellular system using discovery proteomics chemical biology techniques, providing critical information for inflammasome studies.
Medienart: |
E-Artikel |
---|
Erscheinungsjahr: |
2024 |
---|---|
Erschienen: |
2024 |
Enthalten in: |
Zur Gesamtaufnahme - volume:19 |
---|---|
Enthalten in: |
ACS chemical biology - 19(2024), 4 vom: 19. Apr., Seite 962-972 |
Sprache: |
Englisch |
---|
Beteiligte Personen: |
Zhao, Heng [VerfasserIn] |
---|
Links: |
---|
Themen: |
Furans |
---|
Anmerkungen: |
Date Completed 22.04.2024 Date Revised 22.04.2024 published: Print-Electronic Citation Status MEDLINE |
---|
doi: |
10.1021/acschembio.3c00777 |
---|
funding: |
|
---|---|
Förderinstitution / Projekttitel: |
|
PPN (Katalog-ID): |
NLM369993586 |
---|
LEADER | 01000caa a22002652 4500 | ||
---|---|---|---|
001 | NLM369993586 | ||
003 | DE-627 | ||
005 | 20240422232250.0 | ||
007 | cr uuu---uuuuu | ||
008 | 240322s2024 xx |||||o 00| ||eng c | ||
024 | 7 | |a 10.1021/acschembio.3c00777 |2 doi | |
028 | 5 | 2 | |a pubmed24n1383.xml |
035 | |a (DE-627)NLM369993586 | ||
035 | |a (NLM)38509779 | ||
040 | |a DE-627 |b ger |c DE-627 |e rakwb | ||
041 | |a eng | ||
100 | 1 | |a Zhao, Heng |e verfasserin |4 aut | |
245 | 1 | 0 | |a Integrated Proteomics Characterization of NLRP3 Inflammasome Inhibitor MCC950 in Monocytic Cell Line Confirms Direct MCC950 Engagement with Endogenous NLRP3 |
264 | 1 | |c 2024 | |
336 | |a Text |b txt |2 rdacontent | ||
337 | |a ƒaComputermedien |b c |2 rdamedia | ||
338 | |a ƒa Online-Ressource |b cr |2 rdacarrier | ||
500 | |a Date Completed 22.04.2024 | ||
500 | |a Date Revised 22.04.2024 | ||
500 | |a published: Print-Electronic | ||
500 | |a Citation Status MEDLINE | ||
520 | |a Inhibition of the NLRP3 inflammasome is a promising strategy for the development of new treatments for inflammatory diseases. MCC950 is a potent and selective small-molecule inhibitor of the NLRP3 pathway and has been validated in numerous species and disease models. Although the capacity of MCC950 to block NLRP3 signaling is well-established, it is still critical to identify the mechanism of action and molecular targets of MCC950 to inform and derisk drug development. Quantitative proteomics performed in disease-relevant systems provides a powerful method to study both direct and indirect pharmacological responses to small molecules to elucidate the mechanism of action and confirm target engagement. A comprehensive target deconvolution campaign requires the use of complementary chemical biology techniques. Here we applied two orthogonal chemical biology techniques: compressed Cellular Thermal Shift Assay (CETSA) and photoaffinity labeling chemoproteomics, performed under biologically relevant conditions with LPS-primed THP-1 cells, thereby deconvoluting, for the first time, the molecular targets of MCC950 using chemical biology techniques. In-cell chemoproteomics with inlysate CETSA confirmed the suspected mechanism as the disruption of inflammasome formation via NLRP3. Further cCETSA (c indicates compressed) in live cells mapped the stabilization of NLRP3 inflammasome pathway proteins, highlighting modulation of the targeted pathway. This is the first evidence of direct MCC950 engagement with endogenous NLRP3 in a human macrophage cellular system using discovery proteomics chemical biology techniques, providing critical information for inflammasome studies | ||
650 | 4 | |a Journal Article | |
650 | 7 | |a Inflammasomes |2 NLM | |
650 | 7 | |a NLR Family, Pyrin Domain-Containing 3 Protein |2 NLM | |
650 | 7 | |a Sulfones |2 NLM | |
650 | 7 | |a Sulfonamides |2 NLM | |
650 | 7 | |a Furans |2 NLM | |
700 | 1 | |a Kumar, Praveen |e verfasserin |4 aut | |
700 | 1 | |a Sobreira, Tiago Jose Paschoal |e verfasserin |4 aut | |
700 | 1 | |a Smith, Mackenzie |e verfasserin |4 aut | |
700 | 1 | |a Novick, Steven |e verfasserin |4 aut | |
700 | 1 | |a Johansson, Anders |e verfasserin |4 aut | |
700 | 1 | |a Luchniak, Anna |e verfasserin |4 aut | |
700 | 1 | |a Zhang, Andrew |e verfasserin |4 aut | |
700 | 1 | |a Woollard, Kevin J |e verfasserin |4 aut | |
700 | 1 | |a Larsson, Niklas |e verfasserin |4 aut | |
700 | 1 | |a Kawatkar, Aarti |e verfasserin |4 aut | |
773 | 0 | 8 | |i Enthalten in |t ACS chemical biology |d 2006 |g 19(2024), 4 vom: 19. Apr., Seite 962-972 |w (DE-627)NLM167137344 |x 1554-8937 |7 nnns |
773 | 1 | 8 | |g volume:19 |g year:2024 |g number:4 |g day:19 |g month:04 |g pages:962-972 |
856 | 4 | 0 | |u http://dx.doi.org/10.1021/acschembio.3c00777 |3 Volltext |
912 | |a GBV_USEFLAG_A | ||
912 | |a GBV_NLM | ||
951 | |a AR | ||
952 | |d 19 |j 2024 |e 4 |b 19 |c 04 |h 962-972 |